{"schema_version":"secwatch.filing_event.v1","accession":"0001082554-25-000007","form_type":"8-K","ticker":"UTHR","cik":"0001082554","company_name":"UNITED THERAPEUTICS Corp","filed_at":"2025-02-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:02.886019+00:00","generated_at":"2026-05-26T03:12:34.967151+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"United Therapeutics reports record $2.88B revenue in FY2024, up 24% YoY","bullets":["Q4 revenue $735.9M (+20% YoY); net income $301.3M vs $217.1M in Q4 2023.","Full-year net income $1.195B ($24.64 diluted EPS) vs $984.8M in 2023 (diluted EPS $19.81).","Tyvaso franchise revenue grew 31% to $1.62B in 2024, driven by Tyvaso DPI (up 41%).","Completed $1B accelerated share repurchase, repurchasing ~3.55M shares.","Recorded $71.1M litigation accrual for Sandoz; R&D expense up 18% on organ projects."],"urls":{"canonical":"https://secwatch.observer/filing/0001082554-25-000007","json":"https://secwatch.observer/filing/0001082554-25-000007.json","markdown":"https://secwatch.observer/filing/0001082554-25-000007.md","text":"https://secwatch.observer/filing/0001082554-25-000007.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1082554/000108255425000007/0001082554-25-000007-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1082554/000108255425000007/uthr-20250226.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T03:12:34.967151+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}